2 results
Approved WMOCompleted
The primary study objective is to evaluate the Model 106 VNS Therapy® System cardiac-based seizure detection and Automated Magnet Mode (AMM) stimulation in epilepsy patients. These two new features will be evaluated using continuous observational…
Approved WMOCompleted
OX40 agonists have been shown to increase antitumor immunity and improve tumor-free survival in non-clinical models and OX40 agonist monoclonal antibodies (mAbs) are currently being evaluated in Phase I clinical trials. GSK3174998 is a humanized…